CD44
CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.
Overview
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, haematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases.
CIViC holds 17 clinical evidence items and 1 assertion across 9 variants, naming Cisplatin, RG7356 and Docetaxel.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.
- 1 · What it is
CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.
- 2 · What goes wrong in cancer
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.
- 3 · How drugs use it
No product in this corpus aims at CD44 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:1681 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16070 (protein name, function text, keywords and locations (REST API)); CIViC gene CD44 (17 evidence items, 1 assertions, 9 variants; diseases: Stomach Cancer, Ovarian Cancer, Cancer, Melanoma, Colorectal Cancer and 7 more (GraphQL API, CC0))
Biology
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, haematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases. Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signalling pathways promoting calcium mobilisation and actin-mediated cytoskeleton reorganisation essential for cell migration and adhesion. Upon interaction with LGALS9 ligand, activates downstream signalling components including LCK, ERK and MAPK to promotes NK cell activation. Location: Cell membrane; Cell projection, microvillus; Secreted (UniProt). Locus 11p13 (HGNC).
- Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease
- Ovarian cancer: CIViC evidence names this disease
- Colorectal cancer: CIViC evidence names this disease
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
- Prostate cancer: CIViC evidence names this disease
- Bladder & urothelial cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 17 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Pancreatic Carcinoma; Squamous Cell Carcinoma.
Latest papers
topQuery for this target: (TITLE:"CD44" OR ABSTRACT:"CD44" OR TITLE:"CD44 molecule IN blood group" OR ABSTRACT:"CD44 molecule IN blood group" OR TITLE:"CD44 antigen" OR ABSTRACT:"CD44 antigen" OR TITLE:"MC56" OR ABSTRACT:"MC56" OR TITLE:"Pgp1" OR ABSTRACT:"Pgp1" OR TITLE:"PGP-1" OR ABSTRACT:"PGP-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD44, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetEpCAM
Shares Intravasation & circulating tumour cells, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
- TargetHGF
Shares Proteoglycans in cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
- TargetGlypican-3
- PathwayFGF / FGFR signalling
Shares Proteoglycans in cancer, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer.
- TechnologyCancer-associated thrombosis prevention and treatment
Shares Intravasation & circulating tumour cells, Gastric & gastro-oesophageal junction cancer.
- TechnologyAspirin for cancer prevention and adjuvant therapy
Shares Intravasation & circulating tumour cells, Gastric & gastro-oesophageal junction cancer, Prostate cancer, Colorectal cancer.
- PathwayVEGF angiogenesis
Shares Proteoglycans in cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- PathwayThe angiogenic switch & tumour vessels
Shares Intravasation & circulating tumour cells, Hepatocellular carcinoma, Ovarian cancer, Colorectal cancer.